EWING, N.J., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, announced today that the company has been approved for approximately $1.5 million, in non-dilutive financing, through New Jersey’s Technology Business Tax Certificate Transfer Program.
Help employers find you! Check out all the jobs and post your resume.
